Exelixis Inc. (EXEL)
NASDAQ: EXEL
· Real-Time Price · USD
43.62
-0.46 (-1.03%)
At close: Jul 01, 2025, 3:59 PM
43.74
0.28%
After-hours: Jul 01, 2025, 07:42 PM EDT
-1.03% (1D)
| Bid | 42.83 |
| Market Cap | 11.9B |
| Revenue (ttm) | 2.3B |
| Net Income (ttm) | 643.57M |
| EPS (ttm) | 2.19 |
| PE Ratio (ttm) | 19.92 |
| Forward PE | 16.54 |
| Analyst | Buy |
| Ask | 43.75 |
| Volume | 2,815,208 |
| Avg. Volume (20D) | 3,235,324 |
| Open | 44.03 |
| Previous Close | 44.08 |
| Day's Range | 43.31 - 44.41 |
| 52-Week Range | 21.82 - 49.62 |
| Beta | 0.28 |
About EXEL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol EXEL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for EXEL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Exelixis Inc. is scheduled to release its earnings on Aug 5, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+7.43%
Exelixis shares are trading higher after the compa...
Unlock content with
Pro Subscription
1 month ago
+3.61%
Exelixis shares are trading higher after the company recently reported better-than-expected Q1 financial results and raised its FY25 sales guidance with its midpoint above estimates. The company, acting as a collaboration partner of Invenra, initiated the dose-escalation stage of the first-in-human Phase 1 clinical study of XB628. On Thursday, Citigroup raised its price target from $45 to $56.
